Compare MWG & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWG | XBIO |
|---|---|---|
| Founded | 1988 | N/A |
| Country | Singapore | United States |
| Employees | N/A | 2 |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 6.9M |
| IPO Year | 2022 | N/A |
| Metric | MWG | XBIO |
|---|---|---|
| Price | $1.43 | $3.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 34.8K | 14.3K |
| Earning Date | 06-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $1.90 |
| 52 Week High | $2.49 | $13.93 |
| Indicator | MWG | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 45.26 |
| Support Level | $1.37 | $2.96 |
| Resistance Level | $1.43 | $3.44 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 50.85 | 1.02 |
Multi Ways Holdings Ltd is a supplier of a wide range of heavy construction equipment for sales and rental in Singapore and the surrounding region. The wide variety of new and used heavy construction equipment for sale and rental by customers range from: earth-moving equipment such as bulldozers, off-terrain dump trucks, excavators and wheel loaders; material-handling equipment such as crawler cranes, rough terrain cranes, scissor lifts, forklifts, boom-lifts and telescopic handlers; road-building equipment such as motor graders, vibrating compactors, asphalt finishers, skid loaders, backhoe loaders, hand rollers and mini excavators; and generators and compressors, such as air compressors, generators, lighting towers and welding machines.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.